enzymmanagement ag, BASED IN SWITZERLAND
The focus of the enzymmanagement ag is the invention, development and production of bioactive cosmeceutic and topical treatments targeting benign tumors of the fatty tissue up to and including rare diseases - e.g. Multiple Symmetric Lipomatosis (Morbus Madelung; ODD EMA adopted) and Estradiol depending breast cancer.
The enzymmanagement ag is focused on its area of expertise and is looking for international cooperation, marketing and / or distribution partners.
The enzymmanagement ag has access to a large portfolio of issued patents.
All developments of the enzymmanagement ag are based on the intracrinological (endocrinological), biochemical and metabolic potential within the female breast, the skin and its appendices itself; especially the extragonadal sexual hormone production, action and metabolism in the target tissues takes place in human beings only:
only the human adrenal cortex is able to produce so much DHEA that any cell within the target tissues is “flooded” and able to produce Estradiol and DHT by itself. This local production in the human target tissues is autonomous i.e. not controlled by other endocrine glands.